Get the Stockscreener App
1.55
0.00%
0.00
Inhibikase Therapeutics Inc stock is traded at $1.55, with a volume of 194.34K.
It is up +0.00% in the last 24 hours and up +0.65% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.55
Open:
$1.59
24h Volume:
194.34K
Relative Volume:
1.14
Market Cap:
$116.52M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.4952
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
-3.13%
1M Performance:
+0.65%
6M Performance:
-12.43%
1Y Performance:
-33.76%
1-Day Range:
$1.48
$1.5949
1-Week Range:
$1.475
$1.66
52-Week Range:
$1.33
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.55 | 116.52M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.04 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.48 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.84 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.72 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.36 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress - TipRanks
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million By Investing.com - Investing.com Australia
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million - Investing.com India
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - The Globe and Mail
Inhibikase Therapeutics Inc IQT0 Stock Analysis and ForecastGrowth Stock Opportunities & Interactive Learning for Better Returns - earlytimes.in
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
[8-K] Inhibikase Therapeutics, Inc. Reports Material Event | IKT SEC FilingForm 8-K - Stock Titan
[424B5] Inhibikase Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Net current asset value per share of Inhibikase Therapeutics, Inc. – MUN:IQT0 - TradingView
Inhibikase Shares Climb After Revised Drug Timeline, Public Offering - MarketScreener
Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Inhibikase Therapeutics Prices $100 Million Public Offering - MarketScreener
Inhibikase Therapeutics (IKT) Prices $100 Million Public Offerin - GuruFocus
Is Inhibikase Therapeutics Inc. stock a buy before product launchesJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Inhibikase Therapeutics, Inc. (IKT) Stock: Declines Amid $100 Million Public Offering Announcement - parameter.io
Inhibikase Therapeutics (NASDAQ: IKT) prices $100M stock, warrants offering at $1.45 - Stock Titan
Inhibikase Therapeutics announces proposed public offering and pre-funded warrants - MSN
IKT Announces Pricing Below Previous Closing Price in Latest Off - GuruFocus
Is Inhibikase Therapeutics Inc. reversing from oversold territoryTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Inhibikase Therapeutics prices $100 million public offering - Investing.com
Inhibikase Therapeutics prices $100 million public offering By Investing.com - Investing.com Australia
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Inhibikase Therapeutics prices public offering of 46 million shares at $1.45 per share - MarketScreener
IKT Announces New Offering Managed by Leading Financial Firms - GuruFocus
Inhibikase Therapeutics (IKT) Launches Public Offering of Common Stock - GuruFocus
Inhibikase Therapeutics announces proposed public offering of common stock and pre-funded warrants - MarketScreener
Inhibikase Therapeutics (IKT) Launches Public Stock Offering - GuruFocus
Inhibikase Therapeutics (IKT) Plans Global Phase 3 Trial for PAH Treatment - GuruFocus
Inhibikase Therapeutics stock falls after announcing public offering By Investing.com - Investing.com South Africa
Inhibikase Therapeutics stock falls after announcing public offering - Investing.com India
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study - TipRanks
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Inhibikase Therapeutics to Initiate Pivotal Phase 3 Study for IKT-001 in Pulmonary Arterial Hypertension, Potentially Accelerating FDA Approval Timeline - Quiver Quantitative
Inhibikase (NASDAQ: IKT) starts stock, pre-funded warrant offering with 30-day 15% option - Stock Titan
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewswire
Inhibikase Therapeutics (Nasdaq: IKT) Plans Single Pivotal Phase 3 PAH Trial of IKT-001 - Stock Titan
Signal strength of Inhibikase Therapeutics Inc. stock in tech scanners - newser.com
Using data models to predict Inhibikase Therapeutics Inc. stock movementRecession Risk & Scalable Portfolio Growth Ideas - newser.com
Top chart patterns to watch in Inhibikase Therapeutics Inc.Recession Risk & Low Risk Entry Point Tips - newser.com
Is Inhibikase Therapeutics Inc. (IQT0) stock overpriced at current multiples2025 Market Outlook & Smart Money Movement Tracker - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
How to build a dashboard for Inhibikase Therapeutics Inc. stock2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Can volume confirm reversal in Inhibikase Therapeutics Inc.July 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com
Is Inhibikase Therapeutics Inc. stock cheap compared to fundamentalsPortfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
Will Inhibikase Therapeutics Inc. stock recover after recent dropDividend Hike & Growth Oriented Trading Recommendations - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Understanding Inhibikase Therapeutics Inc.’s price movementInflation Watch & Fast Entry Momentum Alerts - newser.com
Key resistance and support levels for Inhibikase Therapeutics Inc. - newser.com
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):